ArticleClimacteric : the journal of the International Menopause Society2015
Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause.
Article in Climacteric : the journal of the International Menopause Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Monocentric, Prospective Pilot Study to Test the Efficacy and Safety of the FotonaSmooth Erbium:YAG Laser for the Treatment of Urethral Pain Syndrome in Women
Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- The use of vaginal lasers in the treatment of urinary incontinence and overactive bladder, systematic review.International urogynecology journal · 2021Pooled it
- The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: An ICS/ISSVD Best Practice Consensus Document.Journal of lower genital tract disease · 2019Pooled it
- A systematic review on vaginal laser therapy for treating stress urinary incontinence: Do we have enough evidence?International urogynecology journal · 2017Pooled it
- Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence.International urogynecology journal · 2017Pooled it
- Number of vaginal lactobacilli in postmenopausal women with vaginal atrophy before and after treatment with erbium-YAG laser: a randomized sham-controlled trial.BMC women's health · 2023Trial
- Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: A pilot study.Lasers in surgery and medicine · 2018Trial
- Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency).Lasers in medical science · 2017Trial
- Anatomical and Patient-Reported Outcomes After Non-Ablative Er:YAG Laser Therapy for Genitourinary Syndrome of Menopause: A Prospective Real-World Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Fractional COFrontiers in reproductive health · 2026Article
- Urinary manifestations of genitourinary syndrome of menopause: a review of the pathophysiology, clinical presentation, and management.Gynecology and pelvic medicine · 2026Review
- Effect of vaginal laser therapy for gynecologic patients on vaginal microbiota: a prospective cohort study.Lasers in medical science · 2025Article
- Modern Conservative Management Strategies for Female Stress Urinary Incontinence: A Systematic Review.Journal of clinical medicine · 2025Review
- Assessment of the Efficacy and Safety of a Dual-Wavelength Diode Laser System for the Treatment of Vulvovaginal Atrophy in Women Without a History of Breast Cancer and in Patients with a History of Breast Cancer.Journal of clinical medicine · 2025Article
- Effect of Innovative Low-level Laser Therapy Protocol for Stress Urinary Incontinence: A Case Series Study : Low-level Laser Therapy for Stress Urinary Incontinence.Galen medical journal · 2025Article
- Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- The 100 top-cited articles in menopausal syndrome: a bibliometric analysis.Reproductive health · 2024Article
- Safety and efficacy of non-ablative COArchives of gynecology and obstetrics · 2024Article
- Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.International journal of women's health · 2024Review
- A study of the objective benefits and safety of Er-YAG laser in the treatment of genitourinary syndrome of menopause.Lasers in medical science · 2023Article
- Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim To evaluate the effects of the vaginal erbium laser (VEL) in the treatment of postmenopausal women suffering from genitourinary syndrome of menopause (GSM). Method GSM was assessed in postmenopausal women before and after VEL (one treatment every 30 days, for 3 months; n = 45); the results were compared with the effects of a standard treatment for GSM (1 g of vaginal gel containing 50 μg of estriol, twice weekly for 3 months; n = 25). GSM was evaluated with subjective (visual analog scale, VAS) and objective (Vaginal Health Index Score, VHIS) measures. In addition, in 19 of these postmenopausal women suffering from stress urinary incontinence (SUI), the degree of incontinence was evaluated with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) before and after VEL treatments. Results VEL treatment induced a significant decrease of VAS of both vaginal dryness and dyspareunia (p < 0.01), with a significant (p < 0.01) increase of VHIS. In postmenopausal women suffering from mild to moderate SUI, VEL treatment was associated with a significant (p < 0.01) improvement of ICIQ-SF scores. The effects were rapid and long lasting, up to the 24th week of the observation period. VEL was well tolerated with less than 3% of patients discontinuing treatment due to adverse events. Conclusion This pilot study demonstrates that VEL induces a significant improvement of GSM, including vaginal dryness, dyspareunia and mild to moderate SUI. Further studies are needed to explore the role of laser treatments in the management of GSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.